补体C3抗体

补体C3抗体

〖别名〗Acylation stimulating protein cleavage product; Acylation-stimulating protein cleavage product; AHUS5; ARMD9; ASP; ASP; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody C3 antibody C3a anaphylatoxin; CO3_HUMAN; Complement C3 alpha chain; Complement C3; Complement C3 beta chain; Complement C3 precursor; Complement C3b alpha chain; Complement C3c alpha' chain fragment 2; Complement C3c fragment; Complement C3d fragment; Complement C3f fragment; Complement C3g fragment; Complement component 3; Complement component 3 precursor; Complement component C3; Complement factor 3; CPAMD1; Plp. 

〖浓度〗1mg/1ml 

〖规格〗0.1ml/100μg     

〖抗体来源〗Goat  

〖克隆类型〗补体C3抗体polyclonal 

〖交叉反应〗Human

〖产品类型〗一抗    

〖研究领域〗细胞生物 免疫学 神经生物学 细胞类型标志物  

〖蛋白分子量〗predicted molecular weight: 187kDa 

〖性状〗Lyophilized or Liquid 

〖免疫原〗human Complement C3 purified from human plasma 

〖亚型〗IgG 

〖纯化方法〗affinity purified by Protein A 

〖储存液〗0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide 

〖产品应用〗WB=1:100-500  ELISA=1:500-1000  IP=1:20-100  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500 

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

〖保存条件〗Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

〖产品介绍〗The complement factor C3 consists of an alpha and a beta chain. C3 is a central factor in the complement cascade. It is central to the alternative pathway that leads to the C3 convertase C3bBb. The classical mannose binding lectin activation pathway leads to the C3 convertase C4b2a. These convertases cleave C3 resulting in C3a and C3b. Further degradation leads to the formation of the alpha chain products C3d, C3g and C3c. C3 is an acute phase protein that is produced by a wide range of tissues, including renal epithelial cells and hepatocytes.

Function : C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. 

Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. 

Acylation stimulating protein (ASP): adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for GPR77. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of GPR77.

Subunit : C3 precursor is first processed by the removal of 4 Arg residues, forming two chains, beta and alpha, linked by a disulfide bond. C3 convertase activates C3 by cleaving the alpha chain, releasing C3a anaphylatoxin and generating C3b (beta chain + alpha' chain). C3dg interacts with CR2 (via the N-terminal Sushi domains 1 and 2). During pregnancy, C3dg exists as a complex (probably a 2:2:2 heterohexamer) with AGT and the proform of PRG2. Interacts with VSIG4. C3b interacts with herpes simplex virus 1 (HHV-1) and herpes simplex virus 2 (HHV-2) envelope glycoprotein C; this interaction inhibits the activation of the complement system. Interacts with S.aureus immunoglobulin-binding protein sbi, this prevents interaction between C3dg and CR2. Interacts with S.aureus fib. Interacts (both C3a and ASP) with GPR77; the interaction occurs with higher affinity for ASP, enhancing the phosphorylation and activation of GPR77, recruitment of ARRB2 to the cell surface and endocytosis of GRP77.

Subcellular Location : Secreted.

Tissue Specificity : Plasma. The acylation stimulating protein (ASP) is expressed in adiopocytes and released into the plasma during both the fasting and postprandial periods.

Post-translational modifications : C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons. 

Phosphorylation sites are present in the extracellular medium.

DISEASE : Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. 

Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. 

Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. 

Note=Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.

Similarity : Contains 1 anaphylatoxin-like domain.

Contains 1 NTR domain.

Database links : NCBI Reference Sequence: NP_000055.2

UniProtKB/Swiss-Prot: P01024.2

补体(complement，C)是由近20种不同血清蛋白组成的多分子系统，约占血清球蛋白总量的10％。补体在血清中的含量相对稳定，不因免疫应答而增加，仅在某些病理情况下才会发生波动。补体系统的基本组成包括9种血清蛋白成分，按发现的先后顺序而分别命名为C1-9。C3是一种β球蛋白，是补体中含量最多、作用最重要的一个组分，是补体两条主要激活途径的中心环节，有重要的生物活性作用，可在肝脏中产生。C3蛋白由α、β2条肽链经二硫键连接而成，本产品能特异性的识别C3的β链。 

做过实验的亲们都知道补体C3抗体反应规律，仔细观察我们会发现当抗原第一次进入机体时,需经一定的潜伏期才能产生抗体,且抗体产生的量也不多,在体内维持的时间也较短。当相同抗原第二次进入机体后,开始时,由于原有抗体中的一部分与再次进入的抗原结合,可使原有抗体量略为降低。随后,抗体效价迅速大量增加,可比初次反应产生的多几倍到几十倍,在体内留存的时间亦较长。因此得出由抗原刺激机体产生的抗体,经过一定时间后可逐渐消失。此时若再次接触抗原,可使已消失的抗体快速上升。如再次刺激机体的抗原与初次相同,则称为特异性回忆反应；若与初次反应不同,则称为非特异性回忆反应。  

现在很多商家都在用不同的方式为补体C3抗体搞活动，做促销优惠。这需要的不仅仅是您的经验，还要您一双慧眼。商家天天在喊亏，客户天天觉得你有赚，我们喊高价，为他人做嫁衣。如今，我们不喊价，实实在在批发价零售卖。价格实在质量好，大品牌有保障，售后有服务，操作有指导。

Ab-(010)-17066 CD34 CD34(多肽抗原) ，规格： 0.5mg ，英文名： CD34

Ab-(010)-17067 CD31(PECAM-1) 血小板内皮细胞黏附分子-1（抗原） ，规格： 0.5mg ，英文名： CD31

Ab-(010)-17068 CD25/IL-2RA(Imterleukm-2 Receptor alpha) CD25/白介素2-受体(抗原) ，规格： 0.5mg ，英文名： CD25/IL-2RA

Ab-(010)-17069 CD20(抗原) CD20（抗原） ，规格： 0.5mg ，英文名： CD20

Ab-(010)-17070 CD8 CD8抗原 ，规格： 0.5mg ，英文名： CD8

Ab-(010)-17071 CD4(Rabbit Anti-Human Mouse rat CD4 Palyclonal Anti-body) CD4抗原 ，规格： 0.5mg ，英文名： CD4

Ab-(010)-17072 CD4 CD4(抗原) ，规格： 0.5mg ，英文名： CD4

Ab-(010)-17073 CD3 epsilon peptide CD3 epsilon(抗原) ，规格： 0.5mg ，英文名： CD3

Ab-(010)-17074 CCK8 (Cholecystokinin-8) 胆囊收缩素/缩胆囊素(八肽) ，规格： 0.5mg ，英文名： CCK8

Ab-(010)-17075 Beta-casein( Beta-casein) β-酪蛋白(抗原) ，规格： 0.5mg ，英文名： Beta-casein

Ab-(010)-17076 cyclin D1 周期素D1（抗原） ，规格： 0.5mg ，英文名： cyclin

Ab-(010)-17077 C-jun/AP-1 (Oncoprotein C-jun：active protein 1) 原癌基因蛋白（活化蛋白1）（抗原） ，规格： 0.5mg ，英文名： C-jun/AP-1

Ab-(010)-17078 C-fos(i mmediate early gene, ieg) 即刻早期基因(是一种原癌基因)抗原 ，规格： 0.5mg ，英文名： C-fos

Ab-(010)-17079 BTG2/TIS21(B-cell translocation gene 2) BTG2（抗原） ，规格： 0.5mg ，英文名： BTG2/TIS21

Ab-(010)-17080 BKCa channels(calcium-activated potassium channel) 钙激活钾通道蛋白 ，规格： 0.5mg ，英文名： BKCa

Ab-(010)-17081 BK channel (stretch-activated Kca channel) BK通道蛋白(抗原) ，规格： 0.5mg ，英文名： BK

Ab-(010)-17082 BGP(Bone Gla-protein) 骨钙素(抗原) ，规格： 0.5mg ，英文名： BGP

Ab-(010)-17083 BADH2 (Betaine-aldehyde dehydrogenase ) BADH2抗原 ，规格： 0.5mg ，英文名： BADH2

Ab-(010)-17084 B7-H4 B7-H4（抗原） ，规格： 0.5mg ，英文名： B7-H4

Ab-(010)-17085 AQP4(aquaporin Protein-4) 水通道蛋白-4（抗原） ，规格： 0.5mg ，英文名： AQP4

Ab-(010)-17086 Annexin V 膜粘连蛋白-5(抗原) ，规格： 0.5mg ，英文名： Annexin

Ab-(010)-17087 Beta1-adrenergic receptor 肾上腺素能受体β1(抗原) ，规格： 0.5mg ，英文名： Beta1-adrenergic

Ab-(010)-17088 Akt/PKC(Protein Kinase C,PKC) 蛋白激酶C（多肽抗原） ，规格： 0.5mg ，补体C3抗体英文名： Akt/PKC

Ab-(010)-17089 Angiotensin II receptor(Ang II ) 血管紧张素Ⅱ受体(抗原) ，规格： 0.5mg ，英文名： Angiotensin

Ab-(010)-17090 Ag-ARC(ARG3.1/ARC, Activity-regulated cytoskeleton-associated protein) ARC(多肽抗原) ，规格： 0.5mg ，英文名： Ag-ARC